Bacteria as Precision Tools for Cancer Therapy
ABSTRACT The discovery at the end of the 20th century of genes that induce cell death revolutionised the biocontaintment of genetically manipulated bacteria for environmental or agricultural applications. These bacterial ‘killer’ genes were then assayed for their potential to target and control mali...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Microbial Biotechnology |
| Online Access: | https://doi.org/10.1111/1751-7915.70090 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832576331911528448 |
|---|---|
| author | Carmen Michán José Prados Juan‐Luis Ramos |
| author_facet | Carmen Michán José Prados Juan‐Luis Ramos |
| author_sort | Carmen Michán |
| collection | DOAJ |
| description | ABSTRACT The discovery at the end of the 20th century of genes that induce cell death revolutionised the biocontaintment of genetically manipulated bacteria for environmental or agricultural applications. These bacterial ‘killer’ genes were then assayed for their potential to target and control malignant cells in human cancers. The identification of the bacteriomes in different human organs and tissues, coupled with the observation that bacteria tend to accumulate near tumours, has opened new avenues for anti‐cancer strategies. This progress, along with recent insights into how cancer cells evade immune response, has prompted innovative therapeutic approaches. Tumour microenvironments are typically nutrient‐rich, characterised by low oxygen tensions and very resistant to immune responses. Two recent studies in MBT highlight the promise of using Salmonella typhimurium and Escherichia coli as vectors in novel cancer treatments. Engineered S. typhimurium strains can generate adjuvant flagellin‐antigen complexes that function as in situ vaccines, hence increasing the immunogenic responses within tumour environment. Similarly, gut E. coli can be used as vectors to targert tumour cells in colon cancer, enabling both diagnostic applications and localised treatments. Both approaches hold significant potential to improve patient survival outcomes. |
| format | Article |
| id | doaj-art-4500483490e74785aa658fa57da7e4f3 |
| institution | Kabale University |
| issn | 1751-7915 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Microbial Biotechnology |
| spelling | doaj-art-4500483490e74785aa658fa57da7e4f32025-01-31T06:26:35ZengWileyMicrobial Biotechnology1751-79152025-01-01181n/an/a10.1111/1751-7915.70090Bacteria as Precision Tools for Cancer TherapyCarmen Michán0José Prados1Juan‐Luis Ramos2Departamento de Bioquímica y Biología Molecular, Campus de Excelencia Internacional Agroalimentario CeiA3 Universidad de Córdoba Córdoba SpainDepartment of Anatomy and Embryology, Faculty of Medicine, Center of Biomedical Research (CIBM), Instituto de Investigación Biosanitaria (IBS) de Granada; Institute of Biopathology and Regenerative Medicine (IBIMER) University of Granada Granada SpainEstación Experimental del Zaidín Consejo Superior de Investigaciones Científicas Granada SpainABSTRACT The discovery at the end of the 20th century of genes that induce cell death revolutionised the biocontaintment of genetically manipulated bacteria for environmental or agricultural applications. These bacterial ‘killer’ genes were then assayed for their potential to target and control malignant cells in human cancers. The identification of the bacteriomes in different human organs and tissues, coupled with the observation that bacteria tend to accumulate near tumours, has opened new avenues for anti‐cancer strategies. This progress, along with recent insights into how cancer cells evade immune response, has prompted innovative therapeutic approaches. Tumour microenvironments are typically nutrient‐rich, characterised by low oxygen tensions and very resistant to immune responses. Two recent studies in MBT highlight the promise of using Salmonella typhimurium and Escherichia coli as vectors in novel cancer treatments. Engineered S. typhimurium strains can generate adjuvant flagellin‐antigen complexes that function as in situ vaccines, hence increasing the immunogenic responses within tumour environment. Similarly, gut E. coli can be used as vectors to targert tumour cells in colon cancer, enabling both diagnostic applications and localised treatments. Both approaches hold significant potential to improve patient survival outcomes.https://doi.org/10.1111/1751-7915.70090 |
| spellingShingle | Carmen Michán José Prados Juan‐Luis Ramos Bacteria as Precision Tools for Cancer Therapy Microbial Biotechnology |
| title | Bacteria as Precision Tools for Cancer Therapy |
| title_full | Bacteria as Precision Tools for Cancer Therapy |
| title_fullStr | Bacteria as Precision Tools for Cancer Therapy |
| title_full_unstemmed | Bacteria as Precision Tools for Cancer Therapy |
| title_short | Bacteria as Precision Tools for Cancer Therapy |
| title_sort | bacteria as precision tools for cancer therapy |
| url | https://doi.org/10.1111/1751-7915.70090 |
| work_keys_str_mv | AT carmenmichan bacteriaasprecisiontoolsforcancertherapy AT joseprados bacteriaasprecisiontoolsforcancertherapy AT juanluisramos bacteriaasprecisiontoolsforcancertherapy |